CytomX Therapeutics Inc - Asset Resilience Ratio
CytomX Therapeutics Inc (CTMX) has an Asset Resilience Ratio of 88.46% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how CytomX Therapeutics Inc's Asset Resilience Ratio has changed over time. Check CytomX Therapeutics Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down CytomX Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CytomX Therapeutics Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $317.88 Million | 88.46% |
| Total Liquid Assets | $317.88 Million | 88.46% |
Asset Resilience Insights
- Very High Liquidity: CytomX Therapeutics Inc maintains exceptional liquid asset reserves at 88.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CytomX Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare CytomX Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for CytomX Therapeutics Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for CytomX Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 82.07% | $124.39 Million | $151.57 Million | +30.15pp |
| 2024-12-31 | 51.91% | $62.57 Million | $120.53 Million | -26.06pp |
| 2023-12-31 | 77.97% | $157.34 Million | $201.79 Million | +39.76pp |
| 2022-12-31 | 38.21% | $99.70 Million | $260.89 Million | +8.84pp |
| 2021-12-31 | 29.37% | $99.70 Million | $339.41 Million | -5.27pp |
| 2020-12-31 | 34.65% | $124.26 Million | $358.66 Million | +3.08pp |
| 2019-12-31 | 31.56% | $107.72 Million | $341.28 Million | -9.69pp |
| 2018-12-31 | 41.25% | $188.55 Million | $457.11 Million | -8.18pp |
| 2017-12-31 | 49.43% | $196.56 Million | $397.64 Million | +10.62pp |
| 2016-12-31 | 38.82% | $77.29 Million | $199.13 Million | -25.52pp |
| 2015-12-31 | 64.34% | $126.89 Million | $197.22 Million | +64.20pp |
| 2014-12-31 | 0.14% | $100.00K | $73.06 Million | -0.57pp |
| 2013-12-31 | 0.71% | $100.00K | $14.18 Million | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell… Read more